Showing results (121-130 of 132) with videos related to
Sort By:
Pageof 14
Eclinicalmedicine|July 9, 2020
Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15-25 years: A phase IV randomized comparative studyNicolas Folschweiller, Julio Teixeira, Smita Joshi, et al.Journal of the National Cancer Institute. Monographs|November 12, 2024
A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccinationSylla G Malvi, Pulikkottil O Esmy, Richard Muwonge, et al.The New England Journal of Medicine|July 20, 2011
Prevention of HIV-1 infection with early antiretroviral therapyMyron S Cohen, Ying Q Chen, Marybeth McCauley, et al.JCO Precision Oncology|April 22, 2026
Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal AdenocarcinomaSamuel L Cytryn, Raktim Borpatragohain, Karmelina Charalambous, et al.Human Vaccines & Immunotherapeutics|December 11, 2023
Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccineNeerja Bhatla, Richard Muwonge, Sylla G Malvi, et al.Plos One|December 29, 2020
Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort studyRichard Muwonge, Partha Basu, Tarik Gheit, et al.The Lancet. Oncology|October 11, 2021
Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort studyPartha Basu, Sylla G Malvi, Smita Joshi, et al.Vaccine|November 29, 2022
Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccinationSmita Joshi, Devasena Anantharaman, Richard Muwonge, et al.Papillomavirus Research (Amsterdam, Netherlands)|March 27, 2018
Are two doses of human papillomavirus vaccine sufficient for girls aged 15-18 years? Results from a cohort study in IndiaNeerja Bhatla, Bhagwan M Nene, Smita Joshi, et al.The Lancet. Oncology|December 15, 2015
Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort studyRengaswamy Sankaranarayanan, Priya Ramesh Prabhu, Michael Pawlita, et al.Pageof 14